Patients having received a liver transplantation (LT) for alcoholic liver disease (ALD) have a high risk of de novo malignancies, especially in the upper aerodigestive tract and lungs due to their smoking and alcohol history. The aim of this retrospective study was to compare a group of patients transplanted for ALD who continue to smoke and who were included in an intensive screening program for tobacco-related cancers implemented at the Grenoble University Hospital and a group of similar patients followed according to usual practice (chest computed tomography [CT] scan every 5 years) at the Edouard Herriot Hospital in Lyon. The intensive screening program consisted of an annual checkup, including a clinical examination by an otorhinolaryngologist, a chest CT scan, and an upper digestive endoscopy. A total of 147 patients were included: 71 patients in Grenoble and 76 patients in Lyon. The cumulative incidence of a first tobacco-related cancer was 12.3% at 3 years, 20.6% at 5 years, 42.6% at 10 years, and 64.0% at 15 years. A curative treatment was possible in 80.0% of the patients in Grenoble versus 57.9% in Lyon (P = 0.068). The rates of curative treatment were 63.6% versus 26.3% (P = 0.062) for lung cancers, 100.0% versus 87.5% (P = 0.498) for lip-mouth-pharynx and larynx cancers, and 66.7% versus 100.0% (P = 1) for esophageal cancers, respectively. In addition, for lung cancers, regardless of study group, 68.7% received a curative treatment when the diagnosis was made by CT scan screening versus 14.3% when it was made because of symptoms (P = 0.008). In conclusion, our study strongly confirms the high rate of tobacco-related de novo malignancies in LT patients for ALD and suggests that the screening of lung cancer by annual chest CT scan could significantly increase the rate of curative treatment.
Alcoholic liver disease (ALD) is one of the main reasons for liver transplantation (LT) in Europe with longterm 5-and 10-year survival rates of 73% and 58%, respectively. (1) The occurrence of de novo malignancies is one of the leading causes of late death after LT. (2, 3) Patients transplanted for ALD have higher de novo malignancy incidence rates than those transplanted for other causes, affecting up to a third of such patients. (2, 4) The development of de novo malignancies in this population is due to several risk factors, of which the most predominant are immunosuppressive drug use, increasing age, and environmental factors such as viral infections as well as alcohol and tobacco use. (4) (5) (6) (7) Smoking behavior is more frequent in patients who received transplantation for ALD, and it is a major risk factor of de novo malignancy development. (5, 8) These patients develop more tobacco-related malignancies, such as lung and upper aerodigestive tract
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cancers, leading to poor prognosis (ie, <20% survival at 5 years). (5, 6, (9) (10) (11) (12) Currently, prevention of de novo malignancies consists of patient education with the avoidance of exposure to risk factors (including smoking cessation) and the modulation of the immunosuppressive regimen with a longterm use of the lowest effective dose of immunosuppressive drugs. (7, 13, 14) A few studies have reported intensive screening programs, including a chest and/or abdominal computed tomography (CT) scan, but none included a control group or focused on patients transplanted for ALD. (15) (16) (17) (18) No optimal screening protocol for these patients has been defined, and whether or not extended surveillance will improve patient survival remains unanswered.
The aim of the present study was to evaluate the feasibility and the impact of an intensive screening program for de novo malignancies related to tobacco in LT patients transplanted for ALD and who actively smoke after LT.
Patients and Methods

studY design
All adult LT patients transplanted because of ALD at either the single center in Grenoble, France, or Edouard Herriot Hospital in Lyon, France, from 1990 to 2010 (Lyon) or 2014 (Grenoble), and active tobacco smokers after LT were identified from medical charts. Patients who died or developed cancer within 6 months of transplantation were excluded. The study was conducted according to the present French recommendations on retrospective cohort studies.
Patients were opportunistically divided into 2 groups, on the basis of the center where they underwent transplantation, and followed. In the single Grenoble center, an intensive screening program of de novo malignancies was established in 2005 in addition to standard follow-up. The intensive screening program focused on tobacco-related malignancies: lung, oropharyngeal, laryngeal, and esophageal cancers. It also consisted of an annual checkup, including a clinical examination by an otorhinolaryngologist, a chest CT scan, and an upper digestive endoscopy with Lugol staining. Patients from Grenoble who died or presented a de novo malignancy (except nonmelanoma skin cancers) before 2005 were excluded. In Lyon, only a chest-abdominal CT scan was performed for systematic follow-up at 1, 5, 10, 15, 20, and 25 years after LT (standard screening group).
data cOllected
For each patient, the following data were collected: age at time of transplantation, sex, date of transplantation, longterm immunosuppressive regimen, presence of metabolic syndrome (including body mass index [BMI], diabetes, arterial hypertension, and dyslipidemia), and alcohol relapse. For patients in the intensive screening program, annual investigations were noted if performed, and results were recorded.
Alcohol consumption after LT was determined at every follow-up visit based on regular blood and urine tests and/or reports from the patient, the patient's relatives and friends, and the primary care physician. Patients were divided into 3 groups according to the degree of alcohol consumption: no evidence of relapse, minor relapse but without heavy drinking, and severe relapse with heavy drinking. Heavy drinking was defined as a declared mean alcoholic consumption of more than 20 (women) or 30 (men) g/day, for at least 6 months.
All de novo malignancies in each group were recorded. Diagnosis of malignancy was established by histological examination of biopsies and/or surgical specimens. The date of biopsy or surgical procedure was considered as that of cancer diagnosis. For each cancer, data were collected on histological type, stage at diagnosis according to the tumor-node-metastasis (TNM) classification, and therapy (surgery, radiotherapy, and/or chemotherapy). Survival of all patients with de novo malignancies related to tobacco was assessed. The length of follow-up was calculated from the date of diagnosis to that of death or last known status. Data were also collected for lung cancers that were diagnosed either by screening or by studying 
studY endpOints
The primary endpoint was the rate of curative treatment of all alcohol-related and tobacco-related cancers. A curative treatment was defined as one that obtained complete remission. These could be either surgery or radiotherapy with or without adjuvant chemotherapy. The secondary endpoint was overall survival. Subgroup analysis was performed for each cancer: lung, lip-mouth-pharynx and larynx, and esophagus. Adherence to screening was calculated for each examination (the number of examinations actually performed divided by the number of examinations that should have been performed for individual patients). An adherence rate of >80% was considered good.
statistical analYsis
Categorical variables are expressed as percentages and compared using the chi-square or Fisher's exact test. Continuous variables are expressed as mean ± standard deviation (SD) and compared using the Student t test or the Mann-Whitney U test in case of non-Gaussian distribution. Patient survival was calculated from the date of LT to that of death or the last clinical visit. Survival curves were constructed using the KaplanMeier method and compared using the log-rank test. A P value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software, version 13.0 (IBM, Armonk, NY).
Results
cHaracteristics OF tHe pOpulatiOn
There were 230 LT patients transplanted for ALD at the Grenoble University Hospital between 1990 and 2014, among whom 71 were active smokers and included in the intensive screening program that started on January 1, 2005 (intensive screening group). Similarly, there were 367 LT patients transplanted for ALD at the Edouard Herriot Hospital between 1990 and 2010, among whom 76 were active smokers (standard screening group). A total of 147 patients were therefore included in the comparative study.
The median duration of follow-up after LT was 119 months (range, 13-249 months) in Lyon and 64 months (range, 8-282 months) in Grenoble. The characteristics of the study population are summarized in Table 1 . In both Grenoble (n = 59, 83%) and Lyon (n = 65, 85.5%), there was a majority of men, and patients in Lyon were significantly younger than in Grenoble (48.7 versus 51.7 years; P = 0.012). There was no significant difference between groups in terms of the components of metabolic syndrome. Regarding maintenance immunosuppressive regimen, patients were almost all treated with a calcineurin inhibitor (tacrolimus or cyclosporine) alone or in combination with mycophenolate mofetil (MMF). There were significantly more patients with double immunosuppression in Lyon than in Grenoble (72.4% versus 32.4%; P < 0.05).
cuMulative incidence and cHaracteristics OF de nOvO Malignancies
In the total study population, 63 (42.9%) patients had at least 1 de novo malignancy (excluding nonmelanoma skin cancers). There was a total of 72 cancers, 63 (87.5%) of which were related to tobacco (56 patients), including 30 (47.6%) lung cancers, 27 (42.9%) lip-mouth-pharynx or larynx cancers, and 6 (9.5%) esophageal cancers. A total of 7 (12.5%) patients had 2 cancers; for 3 patients, they were synchronous. Among the other malignancies, 3 were posttransplant lymphoproliferative disorder, 3 genitourinary cancers (renal, n = 1; bladder, n = 1; ovary, n = 1), 1 breast cancer, and 2 digestive cancers (colon, n = 1; pancreas, n = 1).
The cumulative incidence of a first tobacco-related cancer was 12.3% at 3 years, 20.6% at 5 years, 42.6% at 10 years, and 64.0% at 15 years (Fig. 1) . There was no significant difference between the 2 groups.
The characteristics of tobacco-related de novo malignancies are summarized in NOTE: Data are given as n (%) or mean ± SD. 
adHerence tO intensive screening prOgraM
The mean ± SD adherence to intensive screening was 74.0% ± 25.5% for chest CT scan, 46.0% ± 28.9% for otorhinolaryngologist examination, and 62.0% ± 32.1% for upper digestive endoscopy. A total of 47.7% of the patients had an adherence rate >80% for chest CT scan, 14.9% for otorhinolaryngologist examination, and 36.5% for upper digestive endoscopy.
iMpact OF intensive screening prOgraM lung cancers
In the standard screening group, 19 lung cancers were diagnosed after a median of 77 months after LT: 12 were diagnosed by a symptom, and 7 were metastatic. In the intensive screening group, 11 lung cancers were diagnosed after a median of 52 months after LT: 9 were diagnosed by a chest CT scan, and 2 were diagnosed because of symptoms and were metastatic. There was no interval cancer. Sex, age at LT, initial immunosuppressive regimen, components of metabolic syndrome, and severe alcohol relapse were not significantly associated with lung cancer occurrence.
lip-Mouth-pharynx and larynx cancers
In the standard screening group, 16 lip-mouth-pharynx or larynx cancers were diagnosed after a median of 59 months after LT; 1 was metastatic at diagnosis. In the intensive screening group, 11 lip-mouth-pharynx or larynx cancers were diagnosed after a median of 55 months. Only 5 (45%) were diagnosed by screening, whereas 4 of the 6 others were interval cancers. There was no patient with metastatic disease at time of diagnosis in this group.
esophageal cancers
In the standard screening group, 3 esophageal cancers were diagnosed after a median of 169 months after LT, and 3 patients were diagnosed in the intensive screening group after a median of 102 months after LT. One patient was metastatic in the intensive screening group.
curative treatMent
Among all tobacco-related cancers (n = 63), the rate of curative treatment was higher in the intensive screening group (80.0%) than in the standard screening group (57.9%), but the difference did not reach statistical significance (P = 0.068).
For lung cancers (n = 30), in the intensive screening group, 3 (27.3%) were metastatic at diagnosis, 2 (18.2%) had lymphatic invasion, and 6 (54.5%) were at a localized stage. There were 7 (63.6%) patients who received curative care, and all underwent surgery. In the standard screening group, 11 (57.9%) were metastatic at diagnosis (M+), 2 (10.5%) had lymphatic invasion (N+M0), and 6 (31.6%) were at a localized stage (N0M0). There were 5 patients (26.3% of lung cancers) who received curative treatment: 3 underwent surgery and 2 stereotactic radiotherapy. The rate of curative treatment was higher in the intensive screening group Concerning lip-mouth-pharynx or larynx cancers (n = 27), in the intensive screening group, 4 (36.4%) were at a localized stage, and 7 (63.6%) had lymphatic invasion; all (100%) were treated curatively. In the standard screening group, 4 (25%) were at a localized stage, 11 (68.8%) had lymphatic invasion, and 1 (6.2%) was metastatic at diagnosis; 14 (87.5%) had curative treatment (no significant difference between groups; P = 0.498).
For esophageal cancers (n = 6), in the intensive screening group, 2 (66.7%) were localized cancer and were treated curatively, and 1 was metastatic at the diagnosis. In the standard screening group, there was 1 localized cancer and 2 with lymphatic invasion; all were treated curatively (no significant difference between groups; P = 1).
survival
During follow-up, 24 (33.8%) patients died in the intensive screening group, including 14 (58.3%) cancer-related deaths, and 47 (61.8%) patients died in the standard screening group, including 31 (66.0%) cancer-related deaths. Considering all the patients who presented with a de novo malignancy related to tobacco, the survival rates were 71.6% at 1 year and 12.1% at 5 years in the intensive screening group (the median survival was 21.0 months) versus 67.4% at 1 year and 19.8% at 5 years in the standard screening group (the median survival was 20.3 months). There was no significant difference between groups (logrank P = 0.91; Fig. 2A) .
Considering lung cancers, the survival rates were 67.3% at 1 year and 26.9% at 3 years; in the intensive screening group (in which the median time of survival was 24.8 months), the survival rates were 42.1% at 1 year and 12.0% at 3 years; in the standard screening group (in which the median time of survival was 11.1 months), there was no significant difference between groups (log-rank P = 0.16; Fig. 2B ). Considering lipmouth-pharynx or larynx cancers, the survival rates were 72.7% and 87.5% at 1 year, and 11.4% and 13.5% at 5 years in the intensive screening and standard screening groups, respectively (with median survival times of 21.0 and 22.1 months; no difference between groups; log-rank P = 0.77).
iMpact OF diagnOstic prOcess OF lung cancers
Focusing on the 30 patients with lung cancers regardless of group (intense screening/standard screening), the diagnosis was made because of symptoms in 14 patients (46.7%) and by a screening chest CT scan for 16 (53.3%) patients. Among the latter, 11 (68.8%) patients were detected at a localized stage and received curative treatment versus 2 (14.3%) for symptomatic patients (P = 0.008). The mortality rate for patients with lung cancer diagnosed through screening was 56.2%; for those patients with lung cancer diagnosed through their symptoms, the mortality rate was 92.8% (P = 0.039) ( Table 3 ). The survival rates were 64.0% at 1 year and 56.0% at 2 years when the diagnosis was made by a screening CT scan versus 35.7% at 1 year and 0.0% at 2 years when diagnosis was made by symptoms (log-rank P = 0.003; Fig. 2C ).
Discussion
With the increasing number of longterm survivors after LT, de novo malignancies have become one of the most frequent causes of late mortality. (2) The incidence rate of de novo malignancies in transplanted patients for ALD is higher than transplanted patients for other causes of cirrhosis, and these patients have a higher mortality because of tobacco-related cancers. (2, 5, 6, (9) (10) (11) (12) The present study confirms the high rate of de novo malignancies in patients transplanted for ALD and active smokers (excluding skin cancer). Moreover, these cancers were tobacco-related in the vast majority of patients. These rates are higher than those found in previous studies that report an incidence of de novo malignancies in transplanted patients for ALD ranging from 3% to 16%, depending on the length of follow-up. (2, 4) This difference is mainly due to the selection of our study population that included only patients who continued smoking after transplantation. In addition, the median follow-up in the present study was >10 years, which is sufficient because the median time to occurrence of de novo tobacco-related cancers was 78 months after LT.
The aim of this opportunistic comparative study was to evaluate whether an intensive screening program in this population could favor early diagnosis of malignancies and access to curative treatment. The results strongly suggest the beneficial impact of an intensive screening program for lung cancers as more than twice as many patients were treated curatively in the intensive screening group than with normal follow-up. This difference was not statistically significant probably because of a low statistical power, but it was clinically relevant. As previously reported, diagnosis of lung cancer because of symptoms was associated with advanced disease: A German study reported 14 cases of lung cancer in 666 LT patients with more than 70% detected at a metastatic stage. (19) When the diagnosis was made by a screening CT scan in the present study, two-thirds of the patients were diagnosed at a localized stage (N0M0). In addition, 4 times as many patients had curative treatment when the diagnosis was done by screening CT scan than if this followed symptoms, and this difference was significant. The results presented herein regarding the role of a CT scan-based screening program for lung cancer are not surprising in view of the results of the large study from the National Lung Screening Trial Research Team that was performed on 53,454 patients at risk of lung cancer and which evaluated screening Original article | 1697 with low-dose annual chest CT scan compared with chest radiography. This prospective study found a relative reduction in mortality of 20% with a rate of adherence to screening of >90%. (20) This adherence rate was significantly higher than what is reported in our study, which was 74%. Despite our encouraging results, some questions remain unresolved. First, should we perform screening CT scans in formers smokers? Probably yes, since the study from the National Lung Screening Trial Research Team included participants between 55 and 74 years of age, with a history of smoking of at least 30 pack-years, and former smokers who quit within the previous 15 years. In addition, we reported recently that the risk of de novo malignancies after LT for ALD is quite similar for active and former smokers: The cumulative probability of a first de novo solid organ malignancy after LT was 34.8% for past smokers versus 41.3% for current smokers at 15 years. (21) Another question is to define upstream the best strategies for the management of nodules detected with a screening CT scan. In the present study, we did not evaluate the morbidity induced by diagnostic procedure in case of false positives. Finally, the adherence for annual chest CT scan needs to be discussed. We report here an overall adherence rate of 74.0% ± 25.5% and that only 47.7% of our patients had an adherence rate >80%. The adherence rate was over 90% in the study from the National Lung Screening Trial Research Team, and this should probably be a reasonable objective in our population in order to finally improve survival. The present study also confirms the high incidence of lip-mouth-pharynx or larynx cancers in the study population, which represented more than one-third of all de novo malignancies. We also confirm their pejorative prognosis because nearly all patients had died at the end of follow-up. However, no benefit in an annual otorhinolaryngologist physical examination was found herein because among patients in the intensive screening group, diagnosis was made outside of the screening examination in more than half of the patients and two-thirds of the patients concerned had interval cancer. This could be related to the relatively low adherence rate. For now, no published study has defined the method and value of a screening program for lip-mouth-pharynx or larynx malignancies; it could be hypothesized that a nasofibroscopy would be more effective than a simple clinical examination. In addition, adherence for otorhinolaryngology screening was lower than more invasive screening tests like a CT scan and, moreover, endoscopy. It could be hypothesized that patients showed up for radiology and endoscopy acts but not for the clinical visit.
A very small number of esophageal cancers was found herein, which is also the case more generally in transplant patients. For instance, a German retrospective study of 1926 transplanted patients reported only 9 (0.5%) patients with esophageal cancers, and among these, 8 underwent transplantation for ALD. (22) It will therefore be necessary to study a larger population to demonstrate the benefit of upper digestive endoscopy. Moreover, the problem raised by gastroscopy is its acceptability; in the present study, this investigation was performed without general anesthesia, which reduces cost but could lead to patient refusal to repeat the investigation every year. Nevertheless, adherence to this examination was relatively good.
A more general point is that in light of the high rate of tobacco-induced de novo malignancies, screening is only a part of clinical management, and it must be undoubtedly associated with prevention, notably a more incisive attitude to promote smoking cessation. Herrero et al. evaluated the impact of smoking cessation and observed a reduction in the relative risk of developing de novo tobacco-related malignancies from 8.55 to 4.44 between active and former smokers. (6) Van der Heide et al. reported that among 53 active smokers after transplantation, only 20% definitely stopped 2 years thereafter. (8) Interestingly (but desperately), when offered the opportunity to join a cost-free smoking cessation course, 13% of the patients accepted the offer, 62% refused, and 24% were in doubt. Of particular relevance in the population of LT recipients with a history of ALD is the potential beneficial impact of integrating smoking cessation care in alcohol and other drug treatment settings using an organizational change intervention. (23) Such strategies must therefore be implemented as early as possible during a patient's treatment of addictions. In addition to smoking cessation, modulation of immunosuppression has probably a role to play for the prevention of de novo malignancies by reducing the use of calcineurin inhibitors and conversion to mammalian target of rapamycin inhibitors. (13) Finally, the present study has several limitations. First, this is a retrospective study with a relatively small number of patients. Nevertheless, the follow-up was long. Second, we included patients who actively smoked after LT, but a description of active smoking (especially the amount of cigarettes per day, duration, and so on) after (and also before) LT would have been of great relevance; nevertheless, we do not have such data in our clinical charts. Third, we opportunistically compared 2 groups of patients in 2 different centers with 2 different screening strategies. It cannot be ruled out that other differences in the management of the patients could have had an impact on the results reported herein. For instance, maintenance immunosuppressive regimens were different between centers, and this could have played a role in tumor kinetics. Finally, the impact of adherence for the screening (especially for lip-mouthpharynx or larynx cancers) was not extensively evaluated. This could be of great interest in the future but undoubtedly needs large prospective studies.
In conclusion, the present study confirms the high rate and poor prognosis of tobacco-related de novo malignancies in ALD LT patients and that there is a majority of lung, lip-mouth-pharynx, and larynx cancers. The results suggest that annual screening for lung cancer in this population by chest CT scan is probably highly beneficial. On the other hand, the screening of lip-mouth-pharynx or larynx cancers by annual physical examination and of esophageal cancers by endoscopy had no impact.
